These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
255 related items for PubMed ID: 16371516
1. Effect of highly active antiretroviral therapy on multiple AIDS-defining illnesses among male HIV seroconverters. Cain LE, Cole SR, Chmiel JS, Margolick JB, Rinaldo CR, Detels R. Am J Epidemiol; 2006 Feb 15; 163(4):310-5. PubMed ID: 16371516 [Abstract] [Full Text] [Related]
2. [Survival, progression to AIDS and immunosuppression in HIV-positive individuals before and after the introduction of the highly active antiretroviral therapy (HAART)]. Pezzotti P, Dorrucci M, Donisi A, Cusini M, Mazzarello G, De Luca A, Salassa B, Ursitti MA, Giuliani M, Rezza G, l'Italian Seroconversion Study. Epidemiol Prev; 2003 Feb 15; 27(6):348-55. PubMed ID: 15058363 [Abstract] [Full Text] [Related]
3. [Effectiveness of combined antiretroviral therapy on multiple AIDS-defining illnesses in an HIV seroconverter cohort]. Ferreros I, Hurtado I, del Amo J, Muga R, del Romero J, García P, Alastrué I, Belda J, Guevara M, Pérez S, GEMES. Enferm Infecc Microbiol Clin; 2011 Mar 15; 29(3):179-84. PubMed ID: 21333403 [Abstract] [Full Text] [Related]
4. Pregnancy and HIV disease progression during the era of highly active antiretroviral therapy. Tai JH, Udoji MA, Barkanic G, Byrne DW, Rebeiro PF, Byram BR, Kheshti A, Carter JD, Graves CR, Raffanti SP, Sterling TR. J Infect Dis; 2007 Oct 01; 196(7):1044-52. PubMed ID: 17763327 [Abstract] [Full Text] [Related]
5. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR, Pediatric AIDS Clinical Trials Group 219/219C Study Team. Clin Infect Dis; 2008 Feb 15; 46(4):507-15. PubMed ID: 18199042 [Abstract] [Full Text] [Related]
6. Influence of highly active anti-retroviral therapy (HAART) on the natural history of extra-pulmonary tuberculosis in HIV patients. García de Olalla P, Martínez-González MA, Caylà JA, Jansà JM, Iglesias B, Guerrero R, Marco A, Gatell JM, Ocaña I, Barcelona AIDS-TB Study Group. Int J Tuberc Lung Dis; 2002 Dec 15; 6(12):1051-7. PubMed ID: 12546112 [Abstract] [Full Text] [Related]
7. One-year adherence to clinic visits after highly active antiretroviral therapy: a predictor of clinical progress in HIV patients. Park WB, Choe PG, Kim SH, Jo JH, Bang JH, Kim HB, Kim NJ, Oh M, Choe KW. J Intern Med; 2007 Mar 15; 261(3):268-75. PubMed ID: 17305649 [Abstract] [Full Text] [Related]
8. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. López-Gatell H, Cole SR, Hessol NA, French AL, Greenblatt RM, Landesman S, Preston-Martin S, Anastos K. Am J Epidemiol; 2007 May 15; 165(10):1134-42. PubMed ID: 17339383 [Abstract] [Full Text] [Related]
9. Combination antiretroviral therapy and recent declines in AIDS incidence and mortality. Vittinghoff E, Scheer S, O'Malley P, Colfax G, Holmberg SD, Buchbinder SP. J Infect Dis; 1999 Mar 15; 179(3):717-20. PubMed ID: 9952385 [Abstract] [Full Text] [Related]
10. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. Powles T, Robinson D, Stebbing J, Shamash J, Nelson M, Gazzard B, Mandelia S, Møller H, Bower M. J Clin Oncol; 2009 Feb 20; 27(6):884-90. PubMed ID: 19114688 [Abstract] [Full Text] [Related]
11. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, Muñoz A. Clin Infect Dis; 2007 Aug 01; 45(3):370-6. PubMed ID: 17599317 [Abstract] [Full Text] [Related]
12. Trends of AIDS in Guadeloupe (French West Indies) a longitudinal survey from 1988 to 1997. Deloumeaux J, Foucan L, Sow-Goerger MT, Contamin B, Strobel M. West Indian Med J; 2000 Jun 01; 49(2):148-53. PubMed ID: 10948855 [Abstract] [Full Text] [Related]
13. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients. Ho C, Lee S, Wong Kh, Cheng L, Lam M. HIV Med; 2007 Apr 01; 8(3):181-5. PubMed ID: 17461862 [Abstract] [Full Text] [Related]
14. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. Beck EJ, Mandalia S, Gaudreault M, Brewer C, Zowall H, Gilmore N, Klein MB, Lalonde R, Piché A, Hankins CA. AIDS; 2004 Dec 03; 18(18):2411-8. PubMed ID: 15622317 [Abstract] [Full Text] [Related]
16. Differential improvement in survival among patients with AIDS after the introduction of HAART. Couzigou C, Semaille C, Le Strat Y, Pinget R, Pillonel J, Lot F, Cazein F, Vittecoq D, Desenclos JC, Aids Survival Study Group. AIDS Care; 2007 Apr 03; 19(4):523-31. PubMed ID: 17453593 [Abstract] [Full Text] [Related]
19. Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study. Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L, Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A, Lundgren JD, EuroSIDA Study Group. AIDS; 2008 Oct 18; 22(16):2187-98. PubMed ID: 18832882 [Abstract] [Full Text] [Related]
20. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival. Diamond C, Taylor TH, Aboumrad T, Anton-Culver H. Cancer; 2006 Jan 01; 106(1):128-35. PubMed ID: 16329140 [Abstract] [Full Text] [Related] Page: [Next] [New Search]